ArticleFrontiers in oncology2025

Efficacy and safety of immune checkpoint inhibitor rechallenge therapy in the treatment of advanced acquired immune-resistant non-small cell lung cancer: a retrospective study.

Jian Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.